

### **Ayala Corporation**


**FY2023 Analysts' Briefing** Financial and Operating Results March 13, 2024



https://www.ayala.com/investors/presentations



# Core NIAT up 48% to ₱41 billion driven by strong growth in BPI, Ayala Land, and AC Energy



<sup>1</sup>Includes AC Industrials, AC Health, AC Logistics, MWC, and others <sup>2</sup>Based on AC's effective share of ACEN's net income after deducting its share of ACEIC's bond interest

## BPI, Ayala Land, and ACEN continued to deliver strong earnings; Globe's core earnings were flat, but GSR and EBITDA hit all-time highs



- NIAT up 31%. Ex one-off gain in 2022, NIAT up 44% on higher net interest income (+23%), fee income (+17%) and lower provisions (-56%).
- Loan growth grew 10.2%.
  - Corp up 7%; consumer led by credit cards (+38%), personal loans (+106%), and auto (+24%).
  - FY NIM up **+50bps YoY** to 4.09%.
- NPL ratio remained strong at 1.84% and NPL cover at 156%.
- **CIR at 50.0%** on higher tech and manpower expenses.
- **Sustained ROE** at 15.35%; ROA at 1.93%.
- 11M customer base, up by 1.7M;
  3.8M digital clients.



- **NIAT up 32%** on strong residential bookings and higher leasing occupancy and rents.
- **Property development revenues grew 14%** on healthy bookings and higher project completions.
  - Reservation sales up 9%.
  - 25 project launches worth ₱76B in 2023.
- Leasing revenues up 25% from higher rents and occupancy.
  - Shopping centers (+31%): 84% occupancy.
  - Offices (+6%): 92% occupancy.
  - Hotels & Resorts (+42%): 67% occupancy in hotels, 42% in resorts.
- AREIT's net income up 43%.
   AUM reached ₱87B; planned infusions to boost AUM to ₱117B.



- **NIAT down 29%** due to partial sale of data center assets last year.
  - Core NIAT down 1% while EBITDA up 3% as GSR growth (+3%) was offset by higher OPEX, D&A, and interest expense.
  - EBITDA margin still at 50%.
- Mynt equity earnings up 2.9x to ₱2.4B (7% of NIBT).
  - GCash maintained 5x MAU and 10x DAU vs next finance app.
  - ₱118B loans disbursed to date (+2.1x).
  - 16M insurance policies sold to date (+2.7x).
- 2023 CAPEX **down 30%** to ₱71B
  - CAPEX-to-revenue ratio at 44%, 20ppts lower. .



- **NIAT down 43%** due to one-off revaluation gain last year.
  - Income from operating units up 2.9x on capacity growth.
- Attributable generation up 32% on new plants commissioned and stronger wind regime.
  - Added 743MW in net attributable capacity to total of 4,772MW.
  - Potential delays in new projects due to inclement weather and grid connection issues, but expecting to deliver 3,400MW within 2024-2025.
  - Continued investment in transmission assets, with near-term depreciation expense impact.






- Revenues up 19% to ₱8.6B on higher contributions from pharma, clinics, and hospitals.
- Core attributable EBITDA at ₱722M, up 23%.
- Net income at ₱42M excluding greenfield businesses (KMD & cancer hospital) and one-off items.
- Reported net loss of ₱233M.

#### Pharma Retail

Generika Stores (# of outlets) 804 758 75



• Target to have 1,000 stores by 2026.

• Down from 2019 due to store rationalization.

Hospitals Patient Count (in th) 337 384 364 18 10 15 319 374 349 2019 2022 2023

 Total patient count surpassed pre-COVID levels by 8%.



**00** • Stronger generics sales and higher serve rates due to push SSSG back to prepandemic levels.

Inpatient Outpatient



2019 2022 2023

- Spend remains elevated but lower YoY due to resurgence of less complex cases (pedia, dengue, pneumonia).
- Investments in new equipment to increase value of services.

#### Business Update

st.josephdrug

 Signed investment agreement for a significant majority stake in St. Joseph in Dec 2023; currently undergoing PCC approval.
 Accelerates retail pharma expansion (+112 stores) and gives access to new store format.

#### **Business Update**

Far Eastern University Dr. Nicanor Reyes Medical Foundation Medical Center

- Management Agreement with FEU-NRMF commenced in Feb 2024.
- Strengthens AC Health's hospital footprint as a 300bed Level 3 hospital in Metro Manila.

#### **Pharma Distribution**

2023

**CPR<sup>1</sup> Count** 840 1,043 300


 Robust CPR growth fueled consistent commercial sales growth.

2022

### Clinics

2019

Patient Count



- Foot traffic almost at pre-COVID levels.
- Clinic expansion to accelerate growth of patient count.

#### 29% 12% -35% 2019 2022 2023

Sales Growth

• Double digit growth mainly from commercial sales with higher orders from top corporate clients and leading brands.

#### Average Spend

(in	₱) 1,626	2,169	1,883
	2019	2022	2023

• Average spend higher vs pre-COVID but lower YoY due to **competitive price adjustments.** 

<sup>1</sup>Certificate of Product Registration, indicative of number of molecules






## AC Industrials reduced its core loss on better performance of core units and divestments



- **Core net loss narrowed by +26%** to -₱1.1B primarily coming from losses from MTC-Con and Merlin. Results improved YoY on better performance from core units and exit of STI and MTC-Con in 2Q23.
  - Reported loss at -₱5.5B due to impairment from divestments.
- **IMI:** Income from core business up 14% to \$13M on margin improvement driven by the easing component shortage and termination/renegotiation of unfavorable contracts.
- **AC Motors:** Core net income at ₱201M, up 61% on higher earnings from Kia, Honda and Isuzu and lower losses from VW and Maxus.
  - Reported net loss of -₱99M due a write-down on aging 2-wheel inventory and a one-time adjustment in Kia.
  - 4W revenues up 5% but unit sales down 1% partly due to slowdown of Maxus and Volkswagen sales.

### AC Motors unit sales by brand (in k)







# AC Logistics' profitability remains challenged; asset rationalization to yield better results moving forward




- First round of asset integration into AIR21 complete; ongoing Entrego shutdown.
  - Expected savings from lower cost, improved efficiency, better coverage, and improved service level agreements (unprofitable contracts have been renegotiated or terminated).
  - Rationalization to continue.
- **AC Logistics:** Core equity loss at -₱1.1B, slightly narrower YoY. Reported equity loss of -₱1.7B driven by charges related to Entrego's closure.
  - Entrego: -₱1.1B core loss, 9% narrower YoY.
  - AIR21: 13% growth in revenues following stronger demand from the aviation industry and improvement in on-time deliveries from 74% to 94%. Wider net loss of -₱139M, driven by manpower costs and one-offs. Without this, core net loss was -₱78M.
- **Cold Storage** utilization exceeded expectations; expansion in key locations underway.
  - GMAC will build and operate a 11,798-pallet cold storage facility in Panabo City, Davao del Norte.
  - Triples GMAC's capacity to 17k pallets by 2025 upon its completion







## Ayala's 2024 group CAPEX program up 14%; parent CAPEX flat as AC Health is now able to self-fund



**X** AC Industrials

**ACLogistics** 

0

Others

X ACHealth

**Group CAPEX** at ₱284B for 2024, up 14% driven mainly due to increases in ALI and AC Energy.

- **Ayala Land** Up 16%. 34% allocated to residential (-15ppts), 24% to estate development (+8ppts), 19% to land acquisition (-2ppts), 10% into malls (+4ppts), and 13% into other investments (+5ppts).
- **AC Energy** Up 27% on increased RE capacity buildout and transmission assets.
- Globe Down -23%, in line with plan to reach positive FCF by 2025.
- AC Health Up 60% due to the investment in St. Joseph Drug as well as the expansion and upgrade of clinics and hospitals.
- **BPI** Tech expenses up 29%, equal to 11% of revenue.

Parent CAPEX at ₱13B for 2024, flat against last year.

- **AC Logistics** Up due to growth initiatives in AIR21 and closure of Entrego.
- **AC Industrials** Elevated CAPEX in 2023 due to MTC-Con exit and BYD start-up funding.
- **AC Health** CAPEX to be self-funded.
- Others 63% for investment opportunities.


### Ayala's sustained balance sheet strength, complemented by value realization and diversified funding sources remains, a competitive advantage

#### **Balance Sheet Metrics**

In billions

	End-2022	FY2023		
Consolidated				
Cash	77.0	76.2		
Gross debt	552.5	589.8		
Net debt	475.4	513.6		
Net D/E	0.80	0.76		
Parent				
Cash	11.2	11.7		
Gross debt	160.5	157.9		
Net debt	149.3	146.1		
Net D/E	1.04	0.96		
LTV ratio	11.1%	11.2%		

#### **Profile of Obligations and Credit Lines**





Core BUs – Drive market leadership & sustainable growth

- Align BU KRAs with AC's priorities; provide meaningful representation across BU compensation committees
- Increase board oversight and frequency of portfolio reviews

Younger BUs – Achieve scale and generate positive contributions to AC bottomline

- Exit or reconfigure businesses with limited ability to scale and are profitability drags
- **Scale** younger businesses, AC Health and ACMobility

Portfolio – Value realization and continued portfolio sharpening via VCE framework

- Value achieve \$1B valuation within 10 years
- **Cash** return capital within 7 years
- **Earnings** achieve profitability within 5 years






### Annex




## One-offs for 2023 totaled -₱3 billion, the largest of which came from the impairments for MTC-Con and STI and the loss on partial sale of MWC shares





## Core NIAT down 3% QoQ to ₱10.1 billion on lower contributions from BPI, Ayala Land, and ACEIC-ex-ACEN



<sup>1</sup>Includes AC Industrials, AC Health, AC Logistics, MWC, and others <sup>2</sup>Based on AC's effective share of ACEN's net income after deducting its share of ACEIC's bond interest

### Disclaimer

Statements in this presentation describing the Company's objectives, projections, estimates, and expectations may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results could differ materially from those expressed or implied Important factors that could make a difference to the Company's operations include, among others economic conditions affecting demand/supply and price conditions in the domestic and overseas markets in which the Company operates changes in Government regulations, tax laws, and other statutes and incidental factors.



investorrelations@ayala.com

https://ayala.com/investor-relations